- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01202045
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
July 3, 2013 updated by: Paul Farand
Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients With Indirect Signs of Pulmonary Arterial Hypertension
The purpose of this study is to assess the value in terms of sensitivity, specificity and likelihood ratio of the stress echocardiography in the screening of pulmonary arterial hypertension in patients with systemic sclerosis and indirect signs of pulmonary arterial hypertension.
Study Overview
Status
Withdrawn
Conditions
Detailed Description
Pulmonary artery catheterization (rest and exertion) and treadmill stress echocardiography will be done to all patients of the study.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Systemic slerosis patients with indirect signs of arterial pulmonary hypertension:
- Effort dyspnea (NYHA >= 2/4)
- DLCO < 60%
- FVC% / DLCO% > 1.6
- SPAP > 40 mmhg and < 55 mmhg
Description
Inclusion Criteria:
- At least one of the prespecified indirect sign of pulmonary arterial hypertension
- Able to exercise on treadmill
Exclusion Criteria:
- left ventricular dysfunction at rest
- Absence of pulmonary regurgitant flow
- Pregnancy or breastfeeding
- Smoking with > 60 pack-year
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
systemic sclerosis patients
Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of a 20 mmhg increase in the pulmonary artery pressures (PAP) during stress echocardiography and PAP using right heart catheterization.
Time Frame: 5 years
|
Every patient will have both procedures; stress echocardiography and right heart catheterization.
A positive stress echocardiography is defined as >= 20 mmhg increase in the systolic pulmonary artery pressure (SPAP) (between rest and stress) or an absolute value >= 55 mmhg.
A positive right heart catheterization at rest is defined as a PAPm >25mmhg, wedge < 18 and pulmonary vascular resistances >3 wood units.
Stress catheterization will also be perform and is defined as a PAPm > 30mmhg and wedge <18 mm hg.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of a 20 mmhg increase in the PAP during stress echocardiography and elevated NT-proBNP.
Time Frame: 5 years
|
5 years
|
|
|
Function of the left ventricle (left ventricular ejection fraction) at rest and at stress.
Time Frame: Follow up every year X 5
|
We hypothesize that patients who do not increase their left ventricular ejection fraction at stress have a worst clinical outcome in the follow up.
|
Follow up every year X 5
|
|
Diastolic function at rest and at stress
Time Frame: follow up every year X 5
|
We hypothesize that patients with diastolic dysfunction manifesting at stress have a worst clinical outcome in the follow up.
|
follow up every year X 5
|
|
Function of the right ventricle
Time Frame: Follow up every year X 5
|
We hypothesise that in patients with or without pulmonary hypertension, right ventricular dysfunction is associated with a worse clinical outcome
|
Follow up every year X 5
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Paul Farand, md, msc, Centre de recherche du Centre hospitalier Universitaire de Sherbrooke
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (Actual)
October 1, 2011
Study Completion (Anticipated)
October 1, 2011
Study Registration Dates
First Submitted
September 10, 2010
First Submitted That Met QC Criteria
September 14, 2010
First Posted (Estimate)
September 15, 2010
Study Record Updates
Last Update Posted (Estimate)
July 8, 2013
Last Update Submitted That Met QC Criteria
July 3, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Projet # 10-111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scleroderma, Systemic
-
Hacettepe UniversityRecruitingScleroderma, Localized | Scleroderma | Systemic Sclerosis (SSc) | Scleroderma Systemic | Scleroderma (Limited and Diffuse) | Juvenile Systemic Sclerosis | Systemic Sclerosis - 2013 ACR/EULAR Classification CriteriaTurkey (Türkiye)
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedSYSTEMIC SCLERODERMA | ALLOGENEIC MESENCHYMAL STEM CELLS | ADULTFrance
-
Hacettepe UniversityRecruitingPatient Perspective | Systemic Sclerosis (SSc) | Scleroderma (Limited and Diffuse) | Systemic Sclerosis (Scleroderma)Turkey (Türkiye)
-
Rennes University HospitalCompleted
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Hacettepe UniversityRecruitingScleroderma, Localized | Scleroderma | Functionality | Systemic Sclerosis (SSc) | Scleroderma (Limited and Diffuse)Turkey (Türkiye)
-
Hacettepe UniversityRecruitingScleroderma, Localized | Scleroderma | Swallowing | Systemic Sclerosis (SSc) | Scleroderma (Limited and Diffuse)Turkey (Türkiye)
-
Boston UniversityRegeneron PharmaceuticalsCompletedSystemic Sclerosis | Scleroderma | Diffuse Systemic Sclerosis | Diffuse SclerodermaUnited States
-
University Hospital, LilleRecruiting